Lysergic acid diethylamide as an analgesic agent in patients with terminal illnesses

Pain ManagementVol. 10, No. 1 EditorialLysergic acid diethylamide as an analgesic agent in patients with terminal illnessesSaibal Das & Tanay MaitiSaibal Das *Author for correspondence: Tel.: +919433429401; E-mail Address: saibaldas123@gmail.comhttps://orcid.org/0000-0002-3153-4166Department of Clinical Pharmacology, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, IndiaSearch for more papers by this author & Tanay MaitiDepartment of Psychiatry, All India Institute of Medical Sciences, Bhubaneswar, IndiaSearch for more papers by this authorPublished Online:19 Dec 2019https://doi.org/10.2217/pmt-2019-0043AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articlePapers of special note have been highlighted as: • of interest; •• of considerable interestReferences1. Sholjakova M , Durnev V , Kartalov A , Kuzmanovska B . Pain relief as an integral part of the palliative care. Open Access Maced. J. Med. Sci. 6(4), 739–741 (2018). Crossref, Medline, Google Scholar2. Byock I . Taking psychedelics seriously. J. Palliat. Med. 21(4), 417–421 (2018). • Elaborates integral issues in pain management with lysergic acid diethylamide (LSD) in patients with terminal illness.Crossref, Medline, Google Scholar3. Dutta V . Repression of death consciousness and the psychedelic trip. J. Cancer Res. Ther. 8(3), 336–342 (2012). Crossref, Medline, Google Scholar4. Liester MB . A review of lysergic acid diethylamide (LSD) in the treatment of addictions: historical perspectives and future prospects. Curr. Drug Abuse Rev. 7(3), 146–156 (2014). Crossref, Medline, CAS, Google Scholar5. Das S , Barnwal P , Ramasamy A , Sen S , Mondal S . Lysergic acid diethylamide: a drug of ‘use’? Ther. Adv. Psychopharmacol. 6(3), 214–228 (2016). •• Comprehensive review of the pharmacology, potential therapeutic benefits and adverse effects of LSD.Crossref, Medline, CAS, Google Scholar6. Bogenschutz MP , Ross S . Therapeutic applications of classic hallucinogens. Curr. Top. Behav. Neurosci. 36, 361–391 (2018). Crossref, Medline, CAS, Google Scholar7. LSD used as analgesic. JAMA 187(1), A33 (1964). Crossref, Google Scholar8. Whelan A , Johnson MI . Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role? Pain Manag. 8(3), 217–229 (2018). •• Comprehensive review of the mechanisms, potential roles and studies of LSD and psilocybin in pain management.Link, Google Scholar9. Bradley JR . TNF-mediated inflammatory disease. J. Pathol. 214(2), 149–160 (2008). Crossref, Medline, CAS, Google Scholar10. De Gregorio D , Posa L , Ochoa-Sanchez R et al. The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors. Pharmacol. Res. 113(Pt A), 81–91 (2016). Medline, Google Scholar11. Dos Santos RG , Osório FL , Crippa JAS , Hallak JEC . Classical hallucinogens and neuroimaging: a systematic review of human studies: hallucinogens and neuroimaging. Neurosci. Biobehav. Rev. 71, 715–728 (2016). • Systematic review of neuroimaging studies analyzing the effects of serotonergic hallucinogens in human.Crossref, Medline, Google Scholar12. Brewer JA , Garrison KA . The posterior cingulate cortex as a plausible mechanistic target of meditation: findings from neuroimaging. Ann. NY Acad. Sci. 1307, 19–27 (2014). Crossref, Medline, Google Scholar13. Allen M , Dietz M , Blair KS et al. Cognitive-affective neural plasticity following active-controlled mindfulness intervention. J. Neurosci. 32(44), 15601–15610 (2012). Crossref, Medline, CAS, Google Scholar14. Fields HL . Understanding how opioids contribute to reward and analgesia. Reg. Anesth. Pain Med. 32(3), 242–246 (2007). Crossref, Medline, CAS, Google Scholar15. Mitsi V , Zachariou V . Modulation of pain, nociception, and analgesia by the brain reward center. Neuroscience 338, 81–92 (2016). • Comprehensive review of the neuroanatomical, electrophysiological and molecular adaptations that chronic pain conditions promote in the mesolimbic dopamine system.Crossref, Medline, CAS, Google Scholar16. Buckner RL , Andrews-Hanna JR , Schacter DL . The brain's default network: anatomy, function, and relevance to disease. Ann. NY Acad. Sci. 1124, 1–38 (2008). Crossref, Medline, Google Scholar17. Kast EC , Collins VJ . Study of lysergic acid diethylamide as an analgesic agent. Anesth. Analg. 43, 285–291 (1964). Crossref, Medline, CAS, Google Scholar18. Kast E . Attenuation of anticipation: a therapeutic use of lysergic acid diethylamide. Psychiatr. Q. 41(4), 646–657 (1967). Crossref, Medline, CAS, Google Scholar19. Grof S , Goodman LE , Richards WA , Kurland AA . LSD-assisted psychotherapy in patients with terminal cancer. Int. Pharmacopsychiatry 8(3), 129–144 (1973). Crossref, Medline, CAS, Google Scholar20. Pahnke WN , Kurland AA , Goodman LE , Richards WA . LSD-assisted psychotherapy with terminal cancer patients. Curr. Psychiatr. Ther. 9, 144–152 (1969). Medline, CAS, Google Scholar21. Fanciullacci M , Bene ED , Franchi G , Sicuteri F . Brief report: phantom limp pain: sub-hallucinogenic treatment with lysergic acid diethylamide (LSD-25). Headache 17(3), 118–119 (1977). Crossref, Medline, CAS, Google Scholar22. Schindler EAD , Gottschalk CH , Weil MJ , Shapiro RE , Wright DA , Sewell RA . Indoleamine hallucinogens in cluster headache: results of the clusterbusters medication use survey. J. Psychoactive Drugs 47(5), 372–381 (2015). Crossref, Medline, Google Scholar23. Sewell RA , Halpern JH , Pope HG . Response of cluster headache to psilocybin and LSD. Neurology 66(12), 1920–1922 (2006). Crossref, Medline, Google Scholar24. Cohen S , Ditman KS . Complications associated with lysergic acid diethylamide (LSD-25). JAMA 181, 161–162 (1962). Crossref, Medline, CAS, Google Scholar25. Winkelman M . Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, Peyote, Ibogaine and Ayahuasca. Curr. Drug Abuse Rev. 7(2), 101–116 (2014). Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Vol. 10, No. 1 Follow us on social media for the latest updates Metrics Downloaded 68 times History Received 26 September 2019 Accepted 15 October 2019 Published online 19 December 2019 Published in print January 2020 Information© 2019 Future Medicine LtdFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download